Hansa Biopharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Renee Aguiar-Lucander

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	4.1yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Renee Aguiar-Lucander (62 yo)

less than a year

Tenure

Ms. Renee Aguiar-Lucander has been Chief Executive Officer of Hansa Biopharma AB (publ) since April 24, 2025. She serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Renee Aguiar-Lucander	Chief Executive Officer	less than a year	no data	no data
C. Ballantyne	CFO & Senior VP	1.2yrs	no data	no data
Eva-Maria Joed	Vice President of Finance & Administration	6yrs	no data	no data
Klaus Sindahl	VP & Head of Investor Relations	no data	no data	no data
Anne Lanner	Senior VP & Chief Human Resources Officer	6.3yrs	no data	0.021% € 33.9k
Emanuel Björne	VP & Head of Business Development	no data	no data	no data
Lena Winstedt	Head of Science	no data	no data	no data
Vincenza Nigro	VP & Head of Medical Affairs	no data	no data	no data
Magnus Korsgren	VP & Head of Research and Development	4.1yrs	no data	no data
Hitto Kaufmann	Senior VP	no data	no data	no data

4.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 24H's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Florian Nicolas Reinaud	Independent Director	less than a year	no data	no data
Anders Pedersen	Independent Director	7yrs	SEK 413.00k	0.0037% € 5.9k
Mats Blom	Independent Director	6yrs	SEK 493.00k	0.0015% € 2.3k
Peter Nicklin	Independent Chairman of the Board	2.9yrs	SEK 1.14m	0.036% € 57.7k
Eva Nilsagard	Independent Director	6yrs	SEK 591.00k	0.0044% € 7.1k
Hilary Malone	Independent Director	4yrs	SEK 725.00k	no data
Gunnar Tufveson	Chairman of European Medical Advisory Board in Transplantation	no data	no data	no data
Kathryn Wood	Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation	no data	no data	no data
Christophe Legendre	Member of European Medical Advisory Board in Transplantation	no data	no data	no data
Stanley Jordan	Chairman of US Medical Advisory Board in Transplantation	no data	no data	no data
Robert Montgomery	Member of US Medical Advisory Board in Transplantation	no data	no data	no data
Jonas Wikstrom	Independent Director	less than a year	no data	0.53% € 851.4k

4.0yrs

Average Tenure

59yo

Average Age

Experienced Board: 24H's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 08:40
End of Day Share Price	2025/05/07 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hansa Biopharma AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Christian Lee	ABG Sundal Collier Sponsored
Madhu Kumar	B. Riley Securities, Inc.

Hansa Biopharma Management

Management criteria checks 2/4

Key information

Recent management updates

Hansa Biopharma AB (publ) Announces Chief Executive Officer Changes

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma Nomination Committee Formed

Recent updates

Hansa Biopharma AB (publ) Announces Chief Executive Officer Changes

Hansa Biopharma AB Completes Enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety Study in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Positive Full Results from 15-HMedIdeS-09 Phase 2 Study and comparative Analysis of Imlifidase in Patients with Guillain-Barre Syndrome

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of Imlifidase in Anti-Glomerular Basement Membrane Disease

Genethon and Hansa Biopharma Announce Initiation of A Phase 2 Trial of Imlifidase as A Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Third quarter 2024 earnings released: kr1.53 loss per share (vs kr4.78 loss in 3Q 2023)

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Second quarter 2024 earnings released: kr3.30 loss per share (vs kr4.79 loss in 2Q 2023)

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings released: kr4.78 loss per share (vs kr3.45 loss in 3Q 2022)

New minor risk - Profitability

New minor risk - Profitability

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings released: kr4.79 loss per share (vs kr3.82 loss in 2Q 2022)

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released: kr3.92 loss per share (vs kr3.11 loss in 1Q 2022)

Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021)

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021)

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

First quarter 2022 earnings released: kr3.11 loss per share (vs kr2.34 loss in 1Q 2021)

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Full year 2021 earnings released: kr12.33 loss per share (vs kr9.98 loss in FY 2020)

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources